Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.

MLA

Yamashita, Atsushi, et al. “Molecular and Clinicopathological Analysis Revealed an Immuno-Checkpoint Inhibitor as a Potential Therapeutic Target in a Subset of High-Grade Myxofibrosarcoma.” Virchows Archiv : An International Journal of Pathology, vol. 481, no. 4, Oct. 2022, pp. 1–17. EBSCOhost, https://doi.org/10.1007/s00428-022-03358-9.

APA

Yamashita, A., Suehara, Y., Hayashi, T., Takagi, T., Kubota, D., Sasa, K., Hasegawa, N., Ishijima, M., Yao, T., & Saito, T. (2022). Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. Virchows Archiv : An International Journal of Pathology, 481(4), 1–17. https://doi.org/10.1007/s00428-022-03358-9

Chicago

Yamashita, Atsushi, Yoshiyuki Suehara, Takuo Hayashi, Tatsuya Takagi, Daisuke Kubota, Keita Sasa, Nobuhiko Hasegawa, Muneaki Ishijima, Takashi Yao, and Tsuyoshi Saito. 2022. “Molecular and Clinicopathological Analysis Revealed an Immuno-Checkpoint Inhibitor as a Potential Therapeutic Target in a Subset of High-Grade Myxofibrosarcoma.” Virchows Archiv : An International Journal of Pathology 481 (4): 1–17. doi:10.1007/s00428-022-03358-9.